MedTrace Logo

Deferred Versus Fresh Embryo Transfers

NCT03349905 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2026-03-31

No results posted yet for this study

Summary

Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Previous reports suggest that pregnancy rates are increased following deferred frozen embryo transfers. In addition as compared to fresh embryo transfers, frozen embryo transfers seem to be associated with less affected perinatal outcomes, in particular lower risk of preterm birth, small for gestational age and caesarean section. Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, whether differing embryo transfers could restore optimal ER leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfers, is actually still under investigation.

Conditions

  • Infertility, Female

Interventions

PROCEDURE

fresh transfer

Women randomized in the non experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France) * All of their embryo kept in prolonged culture * A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage) * Supernumerary blastocysts cryopreserved

PROCEDURE

Deferred-frozen embryo transfer

Women randomized in the experimental group will have: * Antagonist stimulation protocol * Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France) * All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture. * A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Khaled POCATE, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-24
Primary Completion
2022-01-19
Completion
2022-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03349905 on ClinicalTrials.gov